Citi ISO 15022 Settlement Instruction Requirements for Multi-Listed Securities (as of SR2014)

Place of Listing

For multi-listed securities, Citi currently have the capability of allowing the inclusion of the place of listing within the settlement instructions for UK & Ireland (Crest) trades to indicate which Sedol the instruction should be processed on through our systems when an ISIN has been instructed.

For example, adding

:94B::PLIS//EXCH/XLON

within the Financial Instrument Attributes Sequence B1 of the MT540-MT543 settlement instruction picks the “GB” Sedol of the ISIN for processing when the ISIN is multi-listed.

Adding

:94B::PLIS//EXCH/XDUB

picks the “IE” Sedol of the security.

This functionality has now been extended to all markets where applicable. For example, Euroclear and Clearstream ICSD processing has similar issues and the place of listing field can now be used to differentiate between the required lines of ISIN for those markets.
**Place of Listing and Currency of Denomination**

For UK and Ireland transactions, issues with STP may also be experienced in relation to securities such as ishares. For this, taking a basic example, against one ISIN you may have an IE Sedol and two GB Sedols, the latter being differentiated by the currency, for example, GBP and USD. As both GB Sedols are London Exchange listed, the Place of Listing field alone cannot be used to identify which Sedol to process on.

As a further aid to STP, the Currency of Denomination field can now be instructed alongside the Place of Listing field to identify which of the two GB Sedols of the security are required. For example, if an instruction contains

:94B::PLIS//EXCH/XLON
:11A::DENO//USD

Citi will select the USD currency line of the GB Sedol to process on.

If

:94B::PLIS//EXCH/XLON
:11A::DENO//GBP

is instructed instead, the GBP part of the GB line is selected.
Alternative Options Using Narrative Fields

Although the preference will be to instruct the correct structured fields we have also created free text alternatives for narrative field :70E::SPRO//. Codewords /SEDL/ and /DENO/ will allow the same processing to occur. The /SEDL/ codeword should be followed by a two character country code and /DENO/ should be followed by a three character currency code.

For example,

:70E::SPRO///SEDL/GB

works in the same way as :94B::PLIS//EXCH/XLON and

:70E::SPRO///DENO/USD

works in the same way as :11A::DENO//USD.

Taken together, ie

:70E::SPRO///SEDL/GB/DENO/USD

this works in the same way as both the :94B::PLIS and :11A::DENO fields being populated.

Any combination will work. For example, you can have both 94B and 11A, 94B and /DENO/xxx, /SEDL/xx and 11A, or just free text.

However, the Currency of Denomination will not work on its own and is required to be populated with the Place of Listing for this part of the multi-listed securities processing enhancement to be effective and also two fields meaning the same thing should not be populated together, for example, both :94B::PLIS//EXCH/xxxx and :70E::SPRO///SEDL/xx etc.
Reporting as “Ireland” (IE) on MT535 Statement of Holdings

All transactions routed to EUI (Euroclear UK & Ireland) through Citi are reported on MT535 Statement of Holdings as a Place of Safekeeping of the Crest BIC, ie:

:94F::SAFE//CUST/CRSTGB22

If there is a requirement to differentiate the Irish holdings from the GB holdings, this can be done by instructing the Place of Safekeeping as Citi Ireland within the MT54x settlement instructions. One of the following field formats should be included for this:

:94F::SAFE//CUST/CIITIE2X

or

:94C::SAFE//IE

or

:94B::SAFE//SHHE/DUBLIN
Any discussion of tax matters in these materials (i) is not intended or written to be used, and cannot be used or relied upon, by you for the purpose of avoiding any tax penalties and (ii) may have been written in connection with the “promotion or marketing” of any transaction contemplated hereby (“Transaction”). Accordingly, you should seek advice based on your particular circumstances from an independent tax advisor.

In any instance where distribution of this communication subject to the rules of the US Commodity Futures Trading Commission (“CFTC”), this communication constitutes an invitation to consider entering into a derivatives transaction under U.S. CFTC Regulations §§ 1.71 and 23.605, where applicable, but is not a binding offer to buy/sell any financial instrument.

Any terms set forth herein are intended for discussion purposes only and are subject to the final terms as set forth in separate definitive written agreements. This presentation is not a commitment to lend, syndicate a financing, underwrite or purchase securities, or commit capital nor does it obligate us to enter into such a commitment, nor are we acting as a fiduciary to you. By accepting this presentation, subject to applicable law or regulation, you agree to keep confidential the information contained herein and the existence of and proposed terms for any Transaction.

Prior to entering into any Transaction, you should determine, without reliance upon us or our affiliates, the economic risks and merits (and independently determine that you are able to assume these risks) as well as the legal, tax and accounting characterizations and consequences of any such Transaction. In this regard, by accepting this presentation, you acknowledge that (a) we are not in the business of providing (and you are not relying on us for) legal, tax or accounting advice, (b) there may be legal, tax or accounting risks associated with any Transaction, (c) you should receive (and rely on) separate and qualified legal, tax and accounting advice and (d) you should apprise senior management in your organization as to such legal, tax and accounting advice (and any risks associated with any Transaction) and our disclaimer as to these matters. By acceptance of these materials, you and we hereby agree that from the commencement of discussions with respect to any Transaction, and notwithstanding any other provision in this presentation, we hereby confirm that no participant in any Transaction shall be limited from disclosing the U.S. tax treatment or U.S. tax structure of such Transaction.

We are required to obtain, verify and record certain information that identifies each entity that enters into a formal business relationship with us. We will ask for your complete name, street address, and taxpayer ID number. We may also request corporate formation documents, or other forms of identification, to verify information provided.

Any prices or levels contained herein are preliminary and indicative only and do not represent bids or offers. These indications are provided solely for your information and consideration, subject to change at any time without notice and are not intended as a solicitation with respect to the purchase or sale of any instrument. The information contained in this presentation may include results of analyses from a quantitative model which represent potential future events that may or may not be realized, and is not a complete analysis of every material fact representing any product. Any estimates included herein constitute our judgment as of the date hereof and are subject to change without any notice. We and/or our affiliates may make a market in these instruments for our customers and for our own account. Accordingly, we may have a position in any such instrument at any time.

Although this material may contain publicly available information about Citi corporate bond research, fixed income strategy or economic and market analysis, Citi policy (i) prohibits employees from offering, directly or indirectly, a favorable or negative research opinion or offering to change an opinion as consideration or inducement for the receipt of business or compensation; and (ii) prohibits analysts from being compensated for specific recommendations or views contained in research reports. So as to reduce the potential for conflicts of interest, as well as to reduce any appearance of conflicts of interest, Citi has enacted policies and procedures designed to limit communications between its investment banking and research personnel to specifically prescribed circumstances.

[TRADEMARK SIGNOFF: add the appropriate signoff for the relevant legal vehicle]